The tumor microenvironment modulation market is poised for growth driven by increasing focus on advanced immunotherapies, tumor biology understanding, and combination cancer treatments. Expansion is ...
Treos Bio, a clinical-stage biotechnology company developing off-the-shelf and personalized active cancer immunotherapies based on its proprietary PEPI Technology, today announced new translational ...
Findings provide mechanistic support for previously reported clinical outcomes of clinical reversal of platinum resistance/refractoriness from ...
Digestive system cancers, including hepatobiliary and gastrointestinal malignancies, remain a major global oncological burden ...
Cancer immunotherapy drugs known as immune checkpoint inhibitors (ICIs) can be miracle drugs for cancer patients, curing some ...
You might think of cancer as a mass of rogue cells that grow uncontrollably. But cancer is more organized and strategic than that. Rather, cancer is a tightly controlled cellular neighborhood that can ...
Manipulating the immune system to treat cancer has generated phenomenal responses in some patients, including complete cures, but those responses do not last for everyone. For example, chimeric ...
Safety, efficacy, and outcomes of 90-yttrium radioembolization in combination with immune checkpoint inhibitors as a definitive first-line treatment approach in non-surgical hepatocellular carcinoma.
The advent of immune checkpoint inhibitors (ICIs) has marked a paradigm shift in cancer treatment, yet a significant portion of breast cancer patients fail to respond to these therapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results